Daily relations among affect, urge, targeted naltrexone, and alcohol use in young adults.
Heavy drinking among young adults is a serious public health problem. Naltrexone, an opioid antagonist, has been shown to reduce drinking in young adults compared to placebo and can be taken on a targeted (i.e., as needed) basis. Understanding risk factors for drinking and naltrexone effects within-person in young adults may help to optimize the use of targeted naltrexone. The current study was a secondary analysis of daily diary data from 127 (n = 40 female) young adults (age 18-25) enrolled in a double-blind clinical trial of daily (25 mg) plus targeted (25 mg) naltrexone versus placebo. Hierarchical linear models were used to examine the effects of daily affect, urge, and taking targeted medication on same-day risk of drinking to intoxication (defined as estimated blood-alcohol-concentration, BAC ≥ .08 g%). Results indicated urge significantly mediated within-person positive affect-drinking relations on a daily level. Specifically, positive affect was associated with greater urge to drink, which in turn was associated with greater odds of BAC ≥ .08 g%. Furthermore, days of greater positive affect and urge were associated with taking a targeted dose of medication, which reduced the likelihood of intoxication by nearly 23% in the naltrexone group compared to placebo. Gender and family history of alcohol dependence were examined as moderators of these daily level effects. These results provide further evidence of naltrexone's ability to reduce alcohol consumption in young adults and identify potential within-person risk processes related to heavy drinking that could inform alcohol-related interventions for this population. (PsycINFO Database Record
Department of Psychiatry.
Krysten W
KW
Bold
Department of Psychiatry.
Lisa M
LM
Fucito
Department of Psychology, Arizona State University.
William R
WR
Corbin
Department of Psychiatry.
Kelly S
KS
DeMartini
Department of Psychiatry.
Robert F
RF
Leeman
Perelman School of Medicine, University of Pennsylvania.
Henry R
HR
Kranzler
Department of Psychiatry.
Stephanie S
SS
O'Malley
D000293:Adolescent; D000328:Adult; D000339:Affect; D000428:Alcohol Drinking / Q000188:drug therapy* / Q000523:psychology*; D003376:Counseling / Q000379:methods; D003463:Cues; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D009271:Naltrexone / Q000008:administration & dosage*; D055815:Young Adult
D009271:Naltrexone
Alcohol. 2012 Nov;46(7):681-6
22819121
Addict Biol. 2014 Sep;19(5):941-54
23489253
J Am Coll Health. 2009 Jul-Aug;58(1):26-32
19592350
Exp Clin Psychopharmacol. 1998 Aug;6(3):306-15
9725114
J Stud Alcohol Drugs. 2014 Jul;75(4):606-14
24988259
J Stud Alcohol. 2004 Jan;65(1):126-35
15000512
J Stud Alcohol. 2005 Jul;66(4):459-69
16240553
Behav Res Methods. 2011 Sep;43(3):692-700
21487904
J Pers Soc Psychol. 1995 Nov;69(5):990-1005
7473043
J Subst Abuse Treat. 2009 Jan;36(1):S15-23; quiz S24-5
19062347
Addict Behav. 2010 Dec;35(12):1045-53
20685044
Am J Addict. 2001 Summer;10(3):258-68
11579624
Psychol Bull. 2009 Jan;135(1):142-56
19210057
Am J Drug Alcohol Abuse. 2004 Aug;30(3):659-84
15540499
J Clin Psychiatry. 2015 Feb;76(2):e207-13
25742208
J Abnorm Psychol. 2003 Aug;112(3):424-36
12943021
Addict Behav. 2008 Aug;33(8):1048-54
18502591
Psychol Rev. 2004 Jan;111(1):33-51
14756584
Q J Stud Alcohol. 1956 Jun;17(2):296-305
13336262
J Stud Alcohol. 2002 Sep;63(5):600-8
12380857
Addiction. 2004 Nov;99(11):1382-92
15500591
Clin Psychol Rev. 2005 Nov;25(7):841-61
16095785
Alcohol Clin Exp Res. 2006 May;30(5):860-5
16634855
Biol Psychiatry. 2007 Sep 15;62(6):694-7
17336941
MMWR Morb Mortal Wkly Rep. 2015 Aug 7;64(30):814-7
26247434
J Stud Alcohol Drugs Suppl. 2009 Jul;(16):12-20
19538908
J Clin Psychopharmacol. 2009 Aug;29(4):350-7
19593174
Alcohol Res. 2013;35(2):201-18
24881329
J Consult Clin Psychol. 2004 Apr;72(2):317-27
15065964
J Abnorm Psychol. 2014 Aug;123(3):676-94
24933278
Addict Behav. 2007 May;32(5):1054-65
16934413
J Pers Soc Psychol. 1986 Dec;51(6):1173-82
3806354
J Stud Alcohol Drugs. 2007 Jan;68(1):56-65
17149518